SeraCare Life Sciences (SRLS) agrees to be acquired for $80.8M by PE firm Linden Capital...


SeraCare Life Sciences (SRLS) agrees to be acquired for $80.8M by PE firm Linden Capital Partners. The $4/share deal reflects a premium of 19% to Friday's closing price. SRLS, which supplies diagnostic control products for HIV, plasma-derived reagents and contract research services, had said last year it was exploring strategic alternatives.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs